You can buy or sell RNN and other stocks, options, ETFs, and crypto commission-free!
Rexahn Pharmaceuticals, Inc., also called Rexahn Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. Read More The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
52 Week High
52 Week Low
Research And Development
Associated PressMar 8
Rexahn Pharmaceuticals Reports 2018 Financial Results
ROCKVILLE, Md., March 08, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced financial results for year ended December 31, 2018. 2018 and Recent Corporate Highlights: RX-3117 – Orally administered targeted nucleoside analogue -- Completed enrollment in the Phase 2a clinical trial of RX-3117 in combination with ABRAXANE® (pa...
Simply Wall StFeb 15
Is Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) A Volatile Stock?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you’re interested in Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. First, we have company speci...
Expected May 3, Pre-Market